HI-Bio
Houston Gilbert has a comprehensive work experience in the field of biostatistics and data management. Houston is currently serving as the Vice President of Biometrics at HIBio since July 2022. Prior to this role, they worked at Arcus Biosciences where they held various positions including Vice President of Biometrics and Data Management, Executive Director, Head of Biometrics, and Senior Director, Head of Biometrics. Before joining Arcus Biosciences, they were a Senior Director of Biostatistics at Bellicum Pharmaceuticals, Inc. In addition, Gilbert worked at Genentech where they held multiple roles such as Associate Director, Principal Statistical Scientist, Senior Statistical Scientist, and Statistical Scientist. Houston began their career as a PhD student in Biostatistics and Computational Biology at the University of California, Berkeley. Furthermore, Gilbert gained experience as a Public Administration Associate/Epidemiology Intern at the CA DHS STD Control Branch and as a Staff Research Associate at the UC Berkeley Division of Infectious Diseases and Immunity. Throughout their career, Gilbert has developed expertise in biomarker research, companion/complementary diagnostic codevelopment, and the development of resampling-based multiple hypothesis testing procedures.
Houston Gilbert has a PhD in Biostatistics with an emphasis in Genomics & Computational Biology from the University of California, Berkeley. Additionally, they hold an MPH in Epidemiology & Biostatistics from the same university. Houston also has a Fulbright Fellowship in the field of Sociology of Science and Biotechnology Policy from Bielefeld University. Prior to these achievements, they obtained a BS in Biology from Harvey Mudd College. Lastly, Houston attended Choate Rosemary Hall, although no specific degree or field of study is provided for this institution.
HI-Bio
HI-Bio was established on the premise that treatments for immune-mediated illnesses have the potential to provide patients with better outcomes. Many IMDs are caused by immune system cells, such as mast cells, neutrophils, plasma cells, and more, which are dysfunctional. These cells are in charge of crucial processes and functions. With the useof medicines, HI-efforts Bio uses a precision medicine strategy to target, modify or deplete key cellular disease drivers.HI-Bio was established in 2021 in San Francisco, California.